Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Locatelli F et al. – The safety profile appears consistent with that of other ESAs. Even if antibodies against Hematide develop during treatment in some patients, they do not cross–react with EPO. No cases of pure red cell aplasia have been described to date.

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address